上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Selpercatinib (Synonyms: LOXO-292) 纯度: 99.87%
Selpercatinib (LOXO-292) 是一种有效的 RET 激酶抑制剂,抑制 RET (WT),RET (V804M) 和 RET (G810R),IC50 分别为 14.0 nM,24.1 nM 和 530.7 nM,详细信息请参考专利文献 WO2018071447A1 中的化合物 Example 163。具有抗肿瘤作用。
Selpercatinib Chemical Structure
CAS No. : 2152628-33-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥690 | In-stock | |
5 mg | ¥600 | In-stock | |
10 mg | ¥1000 | In-stock | |
25 mg | ¥2200 | In-stock | |
50 mg | ¥3500 | In-stock | |
100 mg | ¥6500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Selpercatinib 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Drug Repurposing Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Lung Cancer Compound Library
- Targeted Therapy Drug Library
- Targeted Diversity Library
- Anti-Liver Cancer Compound Library
- Rare Diseases Drug Library
生物活性 |
Selpercatinib (LOXO-292) is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively[1]. Antineoplastic activity[2]. |
IC50 & Target |
IC50: 14.0 nM (RETWT), 24.1 nM (RETV804M), 530.7 nM (RETG810R)[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Trial |
|
||||||||||||||||
分子量 |
525.60 |
||||||||||||||||
Formula |
C29H31N7O3 |
||||||||||||||||
CAS 号 |
2152628-33-4 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 62.5 mg/mL (118.91 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务